12 completed, 6 terminated, 4 active not recruiting, 4 recruiting. 27 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 27 | Completed 12, Terminated 6, Active not recruiting 4, Recruiting 4, Unknown 1 |
| Phase 2 | 2 | Active not recruiting 1, Terminated 1 |
Follow ravulizumab: new trials by email Literature Review of ravulizumab trials Research Report on ravulizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG) Ravulizumab - Generalized Myasthenia Gravis, gMG | Phase 3 | Recruiting | Alexion Pharmaceuticals, Inc. | 20 | 2026-07-27 | 2026-10-21 |
| Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD) Ravulizumab - NMOSD, Neuromyelitis Optica Spectrum Disorder | Phase 3 | Recruiting | Alexion Pharmaceuticals, Inc. | 19 | 2026-07-20 | 2026-09-11 |
| Study of Ravulizumab in Pediatric Participants With Primary IgAN Ravulizumab - IgAN, IgAVN | Phase 3 | Recruiting | Alexion Pharmaceuticals, Inc. | 36 | 2025-06-14 | 2026-07-30 |
| Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation Ravulizumab, Placebo - Delayed Graft Function, DGF | Phase 3 | Recruiting | Alexion Pharmaceuticals, Inc. | 450 | 2025-05-19 | 2026-06-18 |
| Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adults Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Ravulizumab - Paroxysmal Nocturnal Hemoglobinuria, PNH | Phase 3 | Completed | Alexion Pharmaceuticals, Inc. | 18 | 2024-10-10 | 2026-06-05 |
| Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) Ravulizumab, Placebo - Immunoglobulin A Nephropathy, IgAN | Phase 3 | Active not recruiting | Alexion Pharmaceuticals, Inc. | 584 | 2024-03-29 | 2026-10-02 |
| Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis Ravulizumab - Generalized Myasthenia Gravis, gMG | Phase 3 | Active not recruiting | Alexion Pharmaceuticals, Inc. | 12 | 2023-06-24 | 2026-04-17 |
| ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE Placebo, Ravulizumab - Chronic Kidney Disease, CKD | Phase 3 | Terminated | Alexion Pharmaceuticals, Inc. | 555 | 2023-04-06 | 2026-10-29 |
| Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria Cemdisiran, Eculizumab, Pozelimab - Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Terminated | Regeneron Pharmaceuticals | 3 | 2022-10-06 | 2025-04-08 |
| A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment Ravulizumab, Pozelimab, Cemdisiran - Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Active not recruiting | Regeneron Pharmaceuticals | 202 | 2022-08-01 | 2026-04-30 |
| Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD Ravulizumab - Neuromyelitis Optica Spectrum Disorder | Phase 2 / Phase 3 | Active not recruiting | Alexion Pharmaceuticals, Inc. | 12 | 2022-06-23 | 2026-06-24 |
| Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis Ravulizumab, Placebo - Dermatomyositis | Phase 2 / Phase 3 | Terminated | Alexion Pharmaceuticals, Inc. | 38 | 2021-11-19 | 2025-07-09 |
| Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger Ravulizumab, Placebo, Best Supportive Care - Thrombotic Microangiopathy | Phase 3 | Terminated | Alexion Pharmaceuticals, Inc. | 16 | 2021-06-29 | 2024-10-01 |
| Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment LNP023, Eculizumab, Ravulizumab - Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 3 | Completed | Novartis Pharmaceuticals | 97 | 2021-01-25 | 2024-10-09 |
| Ravulizumab and COVID-19 Ravulizumab - Covid19, Thrombotic Microangiopathies | Phase 3 | Unknown | Brigham and Women's Hospital | 32 | 2020-12-18 | 2023-01-04 |
| Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant Ravulizumab, Placebo, Best supportive care - Thrombotic Microangiopathy | Phase 3 | Completed | Alexion Pharmaceuticals, Inc. | 148 | 2020-12-10 | 2026-06-18 |
| Study of Ravulizumab in Pediatric Participants With HSCT-TMA Ravulizumab, Best Supportive Care - Thrombotic Microangiopathy | Phase 3 | Completed | Alexion Pharmaceuticals, Inc. | 41 | 2020-12-07 | 2026-01-12 |
| Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia Ravulizumab, BSC - COVID-19 Severe Pneumonia, Acute Lung Injury | Phase 3 | Terminated | Alexion Pharmaceuticals, Inc. | 202 | 2020-05-10 | 2022-05-24 |
| An Efficacy and Safety Study of Ravulizumab in ALS Participants Placebo, Ravulizumab - Amyotrophic Lateral Sclerosis, ALS | Phase 3 | Terminated | Alexion Pharmaceuticals, Inc. | 382 | 2020-03-30 | 2023-01-10 |
| An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD Ravulizumab - Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder | Phase 3 | Completed | Alexion Pharmaceuticals, Inc. | 58 | 2019-12-09 | 2025-10-14 |
Showing 20 of 27. Sign in to see all of them.
Hemoglobinuria, Paroxysmal (8) · Thrombotic Microangiopathies (4) · Myasthenia Gravis (3) · Neuromyelitis Optica (3) · Acute Kidney Injury (2) · Atypical Hemolytic Uremic Syndrome (2) · COVID-19 (2) · Glomerulonephritis, IGA (2) · Proteinuria (2) · Renal Insufficiency, Chronic (2) · Acute Lung Injury (1) · Amyotrophic Lateral Sclerosis (1) · Anemia (1) · Delayed Graft Function (1) · Demyelinating Diseases (1)
Alexion Pharmaceuticals, Inc. (23) · Regeneron Pharmaceuticals (2) · Brigham and Women's Hospital (1) · Novartis Pharmaceuticals (1)
United States (24) · Italy (20) · Spain (20) · Japan (19) · France (17) · South Korea (17) · United Kingdom (17) · Canada (14) · Germany (14) · Australia (11) · Brazil (10) · Netherlands (10) · Taiwan (10) · China (9) · Belgium (8)
PMID 33783815, PMID 34526067, PMID 31949012, PMID 32299680, PMID 32554923, PMID 32660611, PMID 32869125, PMID 33048203, PMID 33178408, PMID 33407224, PMID 33826106, PMID 34169200, PMID 34473343, PMID 36272026, PMID 36329366, PMID 36852670, PMID 36890354, PMID 36958364, PMID 37094330, PMID 37103755, PMID 37695623, PMID 37804344, PMID 38319212, PMID 38356884, PMID 38477987, PMID 38551806, PMID 39105067, PMID 39455063, PMID 39468592, PMID 39841198, PMID 40447351, PMID 40448185, PMID 40694294, PMID 41782198, PMID 42384439, PMID 42441931
2016 (4), 2019 (3), 2017 (2), 2018 (1), 2023 (1)